Coagulation Changes Induced by Endotoxin and Purified Contact Activation Product

Summary

By use of purified contact activation product (CAP) it was possible to show that activation of the contact phase of the coagulation system can lead to a state of hypo-coagulability very similar to that occurring in the experimental Sanarelli-Shwartz-man phenomenon (SSP). The coagulation changes which occurred suggested that the difference between the effects of CAP administration and the typical experimental SSP appeared to be merely quantitative in nature. However, the fact that in our experiments on the classical SSP no stasis thrombi developed as the most significant sign of increased coagulation activity, may suggest that pathogenetically important differences exist.

• References

• 1 Alexander B, Kliman A, Colman R, Scholtz E, and De Francesco A. 1959. New hemophiloid defects. Some clinicolaboratory and experimental abnormalities in thromboplastin generation. In: Brinkhous K. M, and De Nicola P. (eds.) Hemophilia and other hemorrhagic states. University of North Carolina Press; Chapel Hill.: 137.
• 2 Ashkinazi I. Y, Klemina I. K. 1970; The influence of activated Hageman factor on the blood coagulation system in vivo. (Russ.). Byulleten Eksperimental’noi Biologui mediciny 69 (04) 32.
• 3 Barth P, Kommerell B, and Pfleiderer Th. 1966; The effect of the contact factors of the coagulation system on platelet aggregation. Thrombosis et Diathesis Haemorrhagica 16: 378.
• 4 Barth P, and Kommerell B. 1969; Isolierung des Kontaktaktivierungsproduktes des Gerinnungssystems aus Schweineplasma. Thrombosis et Diathesis Haemorrhagica 21: 500.
• 5 Barth P, Kommerell B, and Oswald M. 1969; Über einen Einstufentest zur Bestimmung des Kontaktaktivierungsproduktes des Gerinnungssystems. Thrombosis et Diathesis Haemorrhagica 21: 508.
• 6 Barth P, Fritsch H, Immich H, Kommerell B, and Marti H. 1970; Purified contact activation product of the coagulation system in experimental thrombosis. Atherosclerosis 12: 225.
• 7 Botti R. E, and Ratnoff O. D. 1964; Studies on the pathogenesis of thrombosis. An experimental hypercoagulable state induced by the intravenous injection of ellagic acid. Journal of Laboratory and Clinical Medicine 64: 384.
• 8 Clattss A. 1957; Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematologica 17: 237.
• 9 Dahlmann W. 1967 Über eine neue Methode zur Bestimmung des Faktors VIII. Thesis, Bonn.
• 10 Feissly R, and Lüdin U. 1949; Microscopie par contacts de phase. Revue d’hematologie 4: 481.
• 11 Hartert H. 1948; Blutgerinnungsstudien mit der Thrombelastographie, einem neuen Untersuchungsverfahren. Klinische Wochenschrift 26: 577.
• 12 Henderson E. S, and Rapaport S. J. 1962; The thrombotic activity of activation product. Journal of Clinical Investigation 41: 235.
• 13 Iatridis S. G. 1966; Ellagic acid-induced acceleration of intravascular clotting and thrombolysis. Hemostase 6: 363.
• 14 Koller F, Loeliger H, and Duckest F. 1951; Experiments on a new clotting factor. Acta Haematologica 6: 1.
• 15 Lasch H. G, Krecke H. J, Rodrigues-Erdmann F, Sessner H. H, and Schütterle G. 1961; Verbrauchskoagulopathien (Pathogenese und Therapie). Folia Haematologica (Neue Folge) 6: 325.
• 16 Lasch H. G, Heene D. L, Huth H, and Sandritter W. 1967; Pathophysiology, clinical manifestation and therapy of consumption-coagulopathy (‘Verbrauchskoagulopathie’). American Journal of Cardiology 20: 381.
• 17 Mammen E. F, and Grammens G. The purification and some properties of bovine Hageman Factor. Thrombosis et Diathesis Haemorrhagica 18: 306.
• 18 McKay D. G, Müller-Berghaus G, and Cruse B. A. 1969; Activation of Hageman factor by ellagic acid and the generalized Shwartzman Reaction. American Journal of Pathology 54: 393.
• 19 Müller-Berghaus G, and Lasch H.-G. 1970; Consumption of Hageman Factor activity in the generalized Shwartzman Reaction induced by Liquoid. Thrombosis et Diathesis Haemorrhagica 23: 386.
• 20 Müller-Berghaus G, and Lasch H. G. 1970; Aktivitätsänderung des Hageman-Faktors nach intravenöser Liquoidinjektion bei mit Cumarin vorbehandelten Kaninchen. Verhandlungen der Deutschen Gesellschaft für innere Medizin 76: 594.
• 21 Nossel H. L. and Niemetz 1965; A normal inhibitor of the blood coagulation contact reaction product. Blood 25: 712.
• 22 Ratnoff O. D. 1958; An enzyme in plasma inactivating Hageman Factor. Journal of Clinical Investigation 37: 923.
• 23 Schnebergee R, and Müller-Berghaus G. 1970; Verhalten der Hageman-Faktor-Aktivität nach intravenöser Endotoxininjektion bei mit Cumarin vorbehandelten Kaninchen. Verhandlungen der Deutschen Gesellschaft für innere Medizin 76: 597.
• 24 Schneider C. L. 1951; “Fibrin embolism” (Disseminated intravascular coagulation) with defibrination as one of the end results during placenta abruptio. Surgery, Gynecology and Obstetrics with International Abstracts of Surgery 92: 27.
• 25 Thomas D. P, and Wessler S. 1964; Stasis thrombi induced by bacterial endotoxin. Circulation Research 14: 486.
• 26 Thomas D. P, Wessler S, and Reimer S. M. 1962; The relationship of activated Factor XII (Hageman) and bacterial endotoxin to hypercoagulability. Federation Proceedings 21: 61.
• 27 Wessler S. 1952; Coagulation changes in isolated venous segments of the dog. Journal of Clinical Investigation 31: 672.
• 28 Wessler S, and Reimer S. M. 1960; The role of human coagulation factors in serum induced thrombosis. Journal of Clinical Investigation 39: 262.
• 29 Wessler S, Yin E. T, Caston L. W, and Nicol I. 1967; A distinction between the precursor and activated forms of clotting factors in the genesis of stasis thrombi. Thrombosis et Diathesis Haemorrhagica 18: 12.